A Study of Disease Progression in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration
Stopped early
Conditions studied: Geographic Atrophy
In brief
This study seeks to better characterize relationships between visual function and the progression (worsening) of geographic atrophy (GA) due to age-related macular degeneration (AMD). The study also will generate new information on the relationship between genetics and GA progression. This is a global, prospective, multicenter, epidemiologic study enrolling 200 participants with GA secondary to AMD. The study visits are scheduled to occur every 6 months. The anticipated duration of the study is up to 60 months.
Key facts
- Study ID
- NCT02399072
- Run by
- Hoffmann-La Roche
- People needed
- 202
- Starts
- 2015-03-30
- Expected to finish
- 2018-02-08
- Last updated by the study team
- 2019-08-09
Who can join
Age: 50 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Well-demarcated area of GA secondary to AMD
- Women of childbearing potential and men must agree to use adequate contraception for at least 30 days after fluorescein dye administration
- The study is recruiting participants in two different cohorts:
- Cohort 1: Participants with unilateral GA OR Cohort 2: Participants with GA in one eye and CNV (active or treated) with or without GA, in the contralateral eye
You may not qualify if…
- Previous participation in any studies of investigational drugs for GA / dry AMD (exception for studies of vitamins and minerals)
- GA in either eye due to causes other than AMD
- History of vitrectomy surgery, submacular surgery, or any surgical intervention for AMD
- Previous laser photocoagulation for CNV, diabetic macular edema, retinal vein occlusion, and/or proliferative diabetic retinopathy
- Any ocular/systemic medical conditions that, in the opinion of the investigator, could contribute to participant's inability to participate in the study or interfere with study assessments.
- Requirement for continuous use of therapy indicated in Prohibited Therapy
Where it is running
- Midwest Vision Research Foundation — Chesterfield, Missouri, United States
- Char Eye Ear &Throat Assoc — Charlotte, North Carolina, United States
- Retina Assoc of Cleveland Inc — Cleveland, Ohio, United States
- Palmetto Retina Center — Florence, South Carolina, United States
- Tennessee Retina PC. — Nashville, Tennessee, United States
- Retina Res Institute of Texas — Abilene, Texas, United States
- Texas Retina Associates — Dallas, Texas, United States
- Retina Consultants of Houston — The Woodlands, Texas, United States
- Strategic Clinical Research Group, LLC — Willow Park, Texas, United States
- West Virginia University Eye Institute — Morgantown, West Virginia, United States
- Organizacion Medica de Investigacion — Buenos Aires, Argentina
- Oftalmos — Capital Federal, Argentina
- Centro Privado de Ojos Romagosa — Córdoba, Argentina
- Onnis Instituto oftalmológico privado — Córdoba, Argentina
- Oftar — Mendoza, Argentina
- Marsden Eye Research Centre — Parramatta, New South Wales, Australia
- Adelaide Eye and Retina Centre — Adelaide, South Australia, Australia
- Royal Victorian Eye and Ear Hospital — East Melbourne, Victoria, Australia
- The Lions Eye Institute — Nedlands, Western Australia, Australia
- Instituto da Visão IPEPO — São Paulo, São Paulo, Brazil
- Hosp Clinicas da FMUSP — São Paulo, São Paulo, Brazil
- University of British Columbia — Vancouver, British Columbia, Canada
- QEII - HSC Department of Ophthalmology — Halifax, Nova Scotia, Canada
- Sunnybrook Health Sciences Centre — Toronto, Ontario, Canada
- Retina Specialty Institute — Pensacola, Florida, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.